Market Overview

Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease


Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon" or the "Company") today
announced supplemental clinical data from the first cohort (KD025 200 mg
QD) of an ongoing Phase 2 clinical trial (KD025-208) of the Company's
lead Rho-associated coiled-coil kinase 2 ("ROCK2") inhibitor, KD025, for
chronic graft-versus-host disease ("cGVHD"). The Company first announced
clinical data from the study on July 11, 2017.

The data points, which were pending at the time of the prior data
release, are as follows:

  • An additional responder sustained a response through 24 weeks of KD025
    treatment. Of responders remaining on KD025 through 24 weeks, 8 of 9
    (89%) sustained responses, up from 7 of 8 patients (88%) previously
  • An additional patient achieved stable disease at week 24. This finding
    brings the number of patients with stable disease at week 24 to three
    patients, up from two patients previously reported, and increases the
    overall clinical benefit (response and stable disease) to 88% (15/17)
    of patients, up from 82% (14/17) of patients.

The full data from the first cohort have been updated to reflect these
points as follows:

KD025-208 is an ongoing Phase 2 clinical trial evaluating the safety,
tolerability and activity of KD025 in adults with steroid-dependent or
steroid-refractory cGVHD and active disease. The dose-finding study
includes 48 patients divided into three cohorts at different dose levels
(KD025 200 mg QD, 200 mg BID and 400 mg QD), enrolled sequentially
following a safety assessment of each cohort.

In a preliminary analysis of data from the first cohort, KD025 200 mg QD
(n=17), KD025 demonstrated clinically meaningful responses in cGVHD
patients, with an Overall Response Rate ("ORR") of 71% (12/17), which
includes complete and partial responders. Of responders remaining on
KD025 through week 24, 8 of 9 (89%) sustained responses. In addition to
the 12 responders, three patients have stable disease and remain on
KD025 through week 24. Overall clinical benefit (response and stable
disease) occurred in 88% (15/17) of patients. Sixty-seven percent (67%;
8/12) of responders saw an improvement in symptoms as measured by the
Lee cGVHD Symptom Scale score. To date, no drug-related serious adverse
events (SAEs) have been recorded, and no drug-related elevations in
liver function tests have been observed. Importantly, 67% (8/12) of
responders had reduction of steroid doses and 67% (4/6) of patients had
reduction of tacrolimus doses.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements
may be preceded by the words "may," "will," "should," "expects,"
"plans," "anticipates," "could," "intends," "targets," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. These factors include statements regarding
KD025, the results of KD025 in KD025-208, including in the second and
third cohorts to be treated, as well as the long-term results of KD025
in the first cohort, and the prospects for KD025 in other indications.
We believe that these factors also include, but are not limited to, (i)
the initiation, timing, progress and results of our preclinical studies
and clinical trials, and our research and development programs; (ii) our
ability to advance product candidates into, and successfully complete,
clinical trials; (iii) our reliance on the success of our product
candidates; (iv) the timing or likelihood of regulatory filings and
approvals; (v) our ability to expand our sales and marketing
capabilities; (vi) the commercialization of our product candidates, if
approved; (vii) the pricing and reimbursement of our product candidates,
if approved; (viii) the implementation of our business model, strategic
plans for our business, product candidates and technology; (ix) the
scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
technology; (x) our ability to operate our business without infringing
the intellectual property rights and proprietary technology of third
parties; (xi) costs associated with defending intellectual property
infringement, product liability and other claims; (xii) regulatory
developments in the United States, Europe and other jurisdictions;
(xiii) estimates of our expenses, future revenues, capital requirements
and our needs for additional financing; (xiv) the potential benefits of
strategic collaboration agreements and our ability to enter into
strategic arrangements; (xv) our ability to maintain and establish
collaborations or obtain additional grant funding; (xvi) the rate and
degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain qualified
employees and key personnel; (xx) our ability to achieve cost savings
and other benefits from our efforts to streamline our operations and to
not harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with
the U.S. Securities and Exchange Commission (SEC), including the
Company's Quarterly Report on Form 10-Q filed pursuant to Section 13 of
the Securities Exchange Act of 1934, as amended, with the SEC on May 15,
2017. Investors and security holders are urged to read these documents
free of charge on the SEC's web site at
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.

View Comments and Join the Discussion!